• Explore /
  • Poster
  • / Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.

Abstract Poster

Authors

null

Jian Li

Peking University Cancer Hospital & Institute, Beijing, China

Jian Li , Xinhua Zhang , Yongjian Zhou , Jun Zhang , Ye Zhou , Ming Wang , Xin Wu , Yanhong Deng , Zhao Huang , Juan Dong , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

NCT04282980

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11543)

DOI

10.1200/JCO.2023.41.16_suppl.11543

Abstract #

11543

Poster Bd #

477

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

First Author: Takahito Awatsu

First Author: Xiangrui Meng

First Author: Masatoshi Kudo

First Author: Arlene O. Siefker-Radtke